Tratamento com Toxina Botulínica em pacientes pós acidente vascular cerebral no CREFES

Authors

  • Fernando Bermudes Cabral Centro de Reabilitação do Estado do Espírito Santo, Universidade Federal do Espírito Santo
  • Raphael de Paula Doyle Maia Centro de Reabilitação do Estado do Espírito Santo, Universidade Federal do Espírito Santo
  • Rosimara Loureiro de Oliveira Centro de Reabilitação do Estado do Espírito Santo
  • Cristiane Chaves Pereira Centro de Reabilitação do Estado do Espírito Santo
  • Soo Yang Lee Centro de Reabilitação do Estado do Espírito Santo

DOI:

https://doi.org/10.11606/issn.2317-0190.v31iSupl.1a225181

Keywords:

Botulinum Toxins, Type A, Stroke, Muscle Spasticity, Dystonia

Abstract

Espasticidade é uma complicação comum após um Acidente Vascular Cerebral (AVC), afetando cerca de 25% dos sobreviventes. Compromete a qualidade de vida, causando rigidez muscular, postura inadequada dos membros, dor, dificuldade de higiene e limitações no auto-cuidado e tarefas diárias. O uso da toxina botulínica tipo A (TBA) é tratamento padrão para esta condição embora ainda pouco difundido. É um tratamento eficaz, seguro, trazendo inúmeros benefícios, como o ganho de função e a melhora na qualidade de vida.

Downloads

Download data is not yet available.

References

Levy J, Karam P, Forestier A, Loze JY, Bensmail D. Botulinum toxin use in patients with post-stroke spasticity: a nationwide retrospective study from France. Front Neurol. 2023;14:1245228. Doi: https://doi.org/10.3389/fneur.2023.1245228

Francisco GE, Balbert A, Bavikatte G, Bensmail D, Carda S, Deltombe T, et al. A practical guide to optimizing the benefits of post-stroke spasticity interventions with botulinum toxin A: An international group consensus. J Rehabil Med. 2021;53(1):jrm00134. Doi: https://doi.org/10.2340/16501977-2753

Bavikatte G, Subramanian G, Ashford S, Allison R, Hicklin D. Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations. J Cent Nerv Syst Dis. 2021;13:11795735211036576. Doi: https://doi.org/10.1177/11795735211036576

Wissel J, Kivi A. Post-Stroke Spastic Movement Disorder and Botulinum Toxin A Therapy: Early Detection And Early Injection. Ann Rehabil Med. 2023;47(5):326-336. Doi: https://doi.org/10.5535/arm.23108

Khan P, Riberto M, Frances JA, Chueire R, Amorim ACFG, Xerez D, et al. The Effectiveness of Botulinum Toxin Type A (BoNT-A) Treatment in Brazilian Patients with Chronic Post-Stroke Spasticity: Results from the Observational, Multicenter, Prospective BCause Study. Toxins (Basel). 2020;12(12):770. Doi: https://doi.org/10.3390/toxins12120770

Trompetto C, Marinelli L, Mori L, Bragazzi N, Maggi G, Cotellessa F, et al. Increasing the Passive Range of Joint Motion in Stroke Patients Using Botulinum Toxin: The Role of Pain Relief. Toxins (Basel). 2023;15(5):335. Doi: https://doi.org/10.3390/to-xins15050335

Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study. J Rehabil Med. 2021;53(2):jrm00157. Doi: https://doi.org/10.2340/16501977-2801

Picelli A, Santamato A, Chemello E, Cinone N, Cisari C, Gandolfi M, et al. Adjuvant treatments associated with botulinum toxin injection for managing spasticity: An overview of the literature. Ann Phys Rehabil Med. 2019;62(4):291-296. Doi: https://doi.org/10.1016/j.rehab.2018.08.004

Published

2024-04-30

Issue

Section

Extended Abstracts

How to Cite

1.
Cabral FB, Maia R de PD, Oliveira RL de, Pereira CC. Tratamento com Toxina Botulínica em pacientes pós acidente vascular cerebral no CREFES. Acta Fisiátr. [Internet]. 2024 Apr. 30 [cited 2025 Mar. 9];31(Supl.1):S102-S104. Available from: https://periodicos.usp.br/actafisiatrica/article/view/225181